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all-cause mortality (RR: 0.89, 95% CI: 0.76 – 1.04, P ¼ 0.979) between
AT and PPCI arm at 1-month (RR: 0.89, 95% CI: 0.76 – 1.04, P ¼ 0.155),
6-12 months (RR: 0.87, 95% CI: 0.38 – 1.98, P ¼ 0.620) and >12 months
(RR: 0.73, 95% CI: 0.49 – 1.09, P ¼ 0.12) follow-up. The 2 groups were
similar with regards to target vessel revascularization (RR: 0.79, 95%
CI: 0.60 – 1.04, P ¼ 0.149) and stroke (RR: 1.45, 95% CI: 0.84 – 2.50, P ¼
0.620) however there was a signiﬁcant reduction of recurrent MI (RR:
0.67, 95% CI: 0.46 – 0.97, P ¼ 0.032) and MACE (Death þ MI þ target
vessel revascularization) rate (RR: 0.81, 95% CI: 0.66 – 0.99, P ¼ 0.031)
in AT arm when compared to PPCI. The net clinical beneﬁt (MACE þ
stroke) was similar in the two groups (RR: 0.97, 95% CI: 0.87 – 1.07, P ¼
0.710).
CONCLUSIONS In this largest till date meta-analysis, including all the
available randomized controlled trial ,we show that AT prior to PPCI in
STEMI is associated with similar mortality, stroke and target revas-
cularization rates however there is a signiﬁcant reduction of MACE
rate in the AT arm primarily driven by reduced rates of recurrent MI.
There was no difference between the two treatment arms in terms of
net clinical beneﬁt.
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BACKGROUND Previous evaluations of endovascular cooling during
primary PCI for acute myocardial infarction (MI) in human and animal
studies suggest a treatment effect on infarct size (IS) related to core
temperature at the time of reperfusion. These observations have not
translated into results of recent randomized trials. We investigated a
comparative dose response relationship between myocardial salvage
and depth of cooling.
METHODS Twenty-four pigs were randomly assigned to 3 groups:
normothermia 38C, mild hypothermia 35C and moderate hypother-
mia 32C. MI was induced by 1-hour balloon occlusion of the mid LAD
followed by reperfusion. A heat-exchange balloon catheter placed in
the inferior vena cava controlled core temperature. Cooling was
initiated 30 minutes after occlusion and maintained for 1 hour fol-
lowed by rewarming to normothermia. IS was assessed at day 6 with
magnetic resonance imaging (CMR) and pathology (TTC).
RESULTS Target temperature was reached in 95 and 298 minutes
for 35C and 32C, respectively. Area-at-risk (AAR) from TTC staining
was equivalent in all groups (306, 287, 266, ANOVA p¼0.217).
Both the 32C and 35C showed signiﬁcant IS reduction per AAR
(4512, 1711, 43, 62% and 91% reduction, respectively, p<0.001)
and a similar reduction per LV mass (145, 53, 11, p<0.001).
Further, 32C showed a signiﬁcant 76% IS per AAR reduction relative
to 35C (p¼0.013) suggesting additional tissue salvage from deeper
cooling. In the linear regression model, target temperature was a
signiﬁcant predictor of IS reduction both per AAR and LV (R2¼ 0.746
and 0.685, respectively, p<0.001). The predicted infarct reduction is
7% of AAR and 2% of LV per 1C drop at reperfusion. Additionally, 32C
had less variability compared to 35C in reducing IS (standard devia-
tion 3 vs 10 relative to AAR and 1 vs 3 relative to LV). In-vivo CMR
imaging evaluation also supported results of signiﬁcant IS reduction
with 32C (104*, 83, 32*, *p<0.001). Cardiac output relative to
baseline was signiﬁcantly preserved in 32C only (-30%19*, -17%32,
-1%28*, *p¼0.041). Both 35C and 32C exhibited signiﬁcant re-
ductions in T2 edema suggesting reduced injury with hypothermia
(p<0.05).CONCLUSIONS Pre-reperfusion rapid therapeutic hypothermia shows
a dose-response infarct size reduction as well as favorable hemody-
namic outcomes for moderate hypothermia more consistently than
mild hypothermia.
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BACKGROUND State-of-art therapeutics for acute myocardial infarc-
tion (AMI) have dramatically improved clinical outcome during the
ﬁrst year after index AMI. However, few data exist on the remnant risk
of recurrent cardiovascular (CV) events in the stable post-MI 1-year
survivors.
METHODS We consecutively enrolled AMI patients who underwent
percutaneous coronary intervention (PCI) in the COREA-AMI (Car-
diOvascular Risk and idEntiﬁcAtion of potential high-risk population
in AMI) registry including nine major university hospitals throughout
South Korea from January 2004 to December 2009. Patients who were
alive and did not experience a recurrent MI or stroke during the ﬁrst
365 days post-index MI were analyzed in this study. We deﬁned “high
risk” as patients with at least one of the following risk factors: age 65
years, diabetes mellitus, prior MI, multi-vessel disease, or renal
dysfunction. The primary endpoint was a composite of CV death, non-
fatal MI, or stroke from Day 366 to study completion.
RESULTS Of 4,748 AMI patients, 4,200 patients were alive at 1 year
after index MI stably without non-fatal MI, or stroke. Median follow-
up duration was 43.8 months (interquartile range 29.8 to 60.5
months). Within the ﬁrst year, combined endpoints of CV events
were 3.0% at low risk and 8.4% at high risk [HR (95%CI) 2.87 (1.91-
4.31), p<0.001]. From 1 year to 4 year after index MI, cumulative
incidence of CV events were 3.9% at low risk and 8.8% at high
risk [2.25 (1.49-3.40), p<0.001]. In multivariable Cox proportional
regression analysis, additional risk factors of stable post-MI patients
were left ventricular dysfunction [1.50 (1.15-1.95), p¼0.002] and
anemia [1.40 (1.08-1.83), p¼0.011]. Patients without taking dual
antiplatelet agent at 1 year have borderline remnant risk [1.31
(0.99-1.73), p¼0.059].
